Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Account Payables (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Account Payables for 16 consecutive years, with $877000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 824.79% to $877000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $42000.0, a 101.68% increase, with the full-year FY2025 number at $42000.0, up 101.68% from a year prior.
  • Change in Account Payables was $877000.0 for Q4 2025 at Anika Therapeutics, up from $231000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.4 million in Q4 2022 to a low of -$2.9 million in Q3 2024.
  • A 5-year average of -$80500.0 and a median of -$6500.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: crashed 911.72% in 2024, then soared 824.79% in 2025.
  • Anika Therapeutics' Change in Account Payables stood at -$398000.0 in 2021, then surged by 459.8% to $1.4 million in 2022, then fell by 8.66% to $1.3 million in 2023, then crashed by 109.25% to -$121000.0 in 2024, then skyrocketed by 824.79% to $877000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Change in Account Payables are $877000.0 (Q4 2025), $231000.0 (Q3 2025), and -$1.1 million (Q2 2025).